Quality of Life and Patient Outcomes in mCRC Treatment

Author(s):

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Melody Chang, RPh, MBA, BCOP

Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

Now Viewing

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
In your experience, how have the third-line therapy options impacted your patients’ quality of life?